Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Home
/
update
/
details

4baseCare Secures $6M in Series A Funding Led by Yali Capital

NextEdge Admin

12 Aug 2024

2 min 17 sec

Bengaluru-based startup 4baseCare, an Illumina Accelerator company specializing in precision oncology through advanced genomics and digital health technology, has secured $6 million in Series A funding. The round was led by Yali Capital, along with other investors. This investment will be used to enhance 4baseCare’s product offerings, scale operations, and expand its presence across India, as well as other Asian and Middle Eastern countries.

Mathew Cyriac, Founding General Partner at Yali Capital, highlighted the significant potential within the cancer genomics sector, stating that 4baseCare’s ability to incorporate data from underrepresented populations will lead to more accurate treatment recommendations. He emphasized the opportunity to build impactful businesses while improving millions of lives.

Hitesh Goswami, CEO and Co-Founder of 4baseCare, expressed that the new funding will further the company’s mission of making personalized cancer care accessible to millions. The company has already made a significant impact, with its genomic tests benefiting over 10,000 cancer patients across Southeast Asia.

The company’s growth is bolstered by a strong advisory board, including Francis deSouza, a seasoned Silicon Valley tech veteran and former CEO of Illumina, who brings over 30 years of expertise in genomics and healthcare. In the coming months, 4baseCare plans to establish genomics laboratories in the Philippines, Nepal, and Dubai. The focus will also be on developing genomics and digital health solutions, leveraging advanced data analytics to improve clinical insights and treatment recommendations.